Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Digestive Diseases and Sciences|April 6, 2011
Application of near-infrared fluorescence imaging using a polymeric nanoparticle-based probe for the diagnosis and therapeutic monitoring of colon cancerSoon Man Yoon, Seung-Jae Myung, In-Wha Kim, et al.
Annals of Laboratory Medicine|June 10, 2021
Early Laboratory Preparedness of the Korea Disease Control and Prevention Agency and Response to Unknown Pneumonia Outbreak from Wuhan, China, in January 2020Il-Hwan Kim, Byung-Hak Kang, Seung Hee Seo, et al.
Nature Communications|February 23, 2025
Dual-mode action of scalable, high-quality engineered stem cell-derived SIRPα-extracellular vesicles for treating acute liver failureSeohyun Kim, Yoon Kyoung Kim, Seonghyun Kim, et al.
Vaccine|October 6, 2019
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary reportMaria Rosario Capeding, Edison Alberto, Arijit Sil, et al.
NPJ Vaccines|January 28, 2022
Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first doseMaria Rosario Capeding, Birkneh Tilahun Tadesse, Arijit Sil, et al.
NPJ Vaccines|May 21, 2026
Long-term cross-variant Fc-mediated immune responses against SARS-CoV-2 induced by a heterologous adenoviral/inactivated virus prime-boost vaccination strategyDoyoung Kim, Jung Hyuk Lee, Junhyeon Lee, et al.
Vaccine|May 20, 2018
Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and childrenMaria Rosario Capeding, Samuel Teshome, Tarun Saluja, et al.
Vaccine|May 30, 2025
Immune persistence after 5 years of vaccination by Vi-DT vaccine among children below 2 years: Result from long-term observational studyRejwana Haque Pial, Maria Rosario Capeding, Katerina Rok Song, et al.
Vaccine|September 5, 2022
Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infantsTarun Saluja, Ganesh Kumar Rai, Shipra Chaudhary, et al.
Eclinicalmedicine|November 5, 2020
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind StudyMaria Rosario Capeding, Arijit Sil, Birkneh Tilahun Tadesse, et al.
Pageof 5